Overview

Price chart · mood · technical indicators

ANIP

ANI Pharmaceuticals Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$77.9710.30%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$56.71$99.50

Current: $77.97

Idea: SMA

1Y Return

+13.4%

Sharpe 3Y

0.55

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

ANIP

+10.30%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio23.48Forward 8.91

EPS (TTM)$3.32-16.9% YoY

Profit margin8.9%HEALTHCARE

Market cap$1.77BSmall cap

Wall Street coverage

$110.62median target· current $66.52 (+66.3%)8 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 8.91
PEG ratio: 1.06
P/B: 3.30
P/S (TTM): 2.01
EV/EBITDA: 10.17

Profitability & growth

ROE (TTM): 16.2%
Operating margin: 12.0%
Revenue growth YoY: 29.6%
Dividend yield: —
Beta: 0.43

Last earnings

Feb 26, 2026 · Estimate $2.04 · Reported $2.33

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

49 articles · sorted by date

Page 1 of 3 · 49 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About ANI Pharmaceuticals Inc

Company profile

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 210 MAIN STREET WEST, BAUDETTE, MN
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$1.77B

Shares outstanding$22.8M

52W high$99.50

52W low$56.71

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

ANIP

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

9 Best Drug Stocks to Buy According to Analysts

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below 200-Day Moving Average - Here's Why

ANIP Price Today: ANI Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals schedules May 8 webcast on Q1 2026 results

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

How Investors Are Reacting To ANI Pharmaceuticals (ANIP) New Generics Push And ILUVIEN Trial Data

ANI Pharmaceuticals launches generic pimozide tablets By Investing.com

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?

ANI launches generic Orap drug with 180 days of exclusivity

ANI Pharmaceuticals launches generic pimozide tablets

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics

ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Zacks Research to Strong-Buy Rating

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules

About ANI Pharmaceuticals Inc

Classification

Company profile

ANIP

Market Comparison

ANIP Market Analysis

Overview

ANIP

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

9 Best Drug Stocks to Buy According to Analysts

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below 200-Day Moving Average - Here's Why

ANIP Price Today: ANI Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

ANI Pharmaceuticals schedules May 8 webcast on Q1 2026 results

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

How Investors Are Reacting To ANI Pharmaceuticals (ANIP) New Generics Push And ILUVIEN Trial Data

ANI Pharmaceuticals launches generic pimozide tablets By Investing.com

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?

ANI launches generic Orap drug with 180 days of exclusivity

ANI Pharmaceuticals launches generic pimozide tablets

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics

ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Zacks Research to Strong-Buy Rating

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules

About ANI Pharmaceuticals Inc

Classification

Company profile

ANIP

Market Comparison